Maridebart Cafraglutide

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau, according to a presentation.

A slew of new medications currently in development may allow health care providers to go beyond glycemic management in the treatment of type 2 diabetes, according to a speaker.

Adults with obesity who received an injectable GIP receptor antagonist/GLP-1 receptor agonist every 4 weeks had a decrease in body weight that was maintained for up to 150 days, according to study findings published in Nature Metabolism.

Adults with obesity can lose 15% or more of their body weight with nutrient-stimulated hormone-based therapies, but reducing body weight is not the only goal providers should have when treating obesity, according to a speaker.